127116-19-2

Basic information

• Product Name: 1-Piperazineethanol,4-(6-chloro-2-methyl-4-pyrimidinyl)-
• Synonyms: 2-[4-(6-Chloro-2-methylpyrimidin-4-yl)piperazin-1-yl]ethanol
• CAS NO: 127116-19-2
• Molecular Formula: C11H17 Cl N4 O
• Molecular Weight: 256.735
• Mol File: 127116-19-2.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 1-Piperazineethanol,4-(6-chloro-2-methyl-4-pyrimidinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazineethanol,4-(6-chloro-2-methyl-4-pyrimidinyl)-(127116-19-2)
• EPA Substance Registry System: 1-Piperazineethanol,4-(6-chloro-2-methyl-4-pyrimidinyl)-(127116-19-2)

Safety Data

• Hazardous Substances Data: 127116-19-2(Hazardous Substances Data)

Usage

Molecular Structure

The compound consists of a piperazine ring, an ethanol group, and a pyrimidine ring.

Classification

It is classified as a pyridine compound.

Usage

Commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals.

Medicinal Properties

Known for its antiviral and antiparasitic properties.

Applications

Used as a key ingredient in various medicines and pesticides.

Value

Valuable in the fields of medicine and agriculture due to its versatile applications.

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 302962-49-8 dasatanib 
• 1245157-85-0 N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide 

Relevant articles and documents

Synthesis of N-pyrimidin[1,3,4]oxadiazoles and N-pyrimidin[1,3,4]-thiadiazoles from 1,3,4-oxadiazol-2-amines and 1,3,4-thiadiazol-2-amines via Pd-catalyzed heteroarylamination

An efficient and practical procedure was developed to prepare various N-pyrimidin[1,3,4]oxadiazole and thiadiazole scaffolds using a Buchwald-type coupling. The products of this reaction are otherwise difficult to access and could be used as building bloc

Synthesis method of dasatinib intermediate

The invention discloses a synthesis method of a dasatinib intermediate. The method comprises the following steps: taking 2-methyl-4-amino-6-chloropyridine and bi(2-chloroethyl)amine to react to generate 2-methyl-6-chloro-pyridine-4-yl piperazine; and taking the 2-methyl-6-chloro-pyridine-4-yl piperazine and 2-ethylene chlorohydrin to react to generate 2-[4-(2-methyl-6-chloro-pyridine-4-yl)piperazine-1-yl]ethanol. The method disclosed by the invention has the advantages of simplicity and easiness of obtaining raw materials, simplicity in operation, high product yield, high purity and easiness of industrial production.

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.